Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A recombinant protein subunit vaccine consisting of the hepatitis B surface antigen (HBsAg), used for active immunization to prevent infection caused by all known subtypes of the hepatitis B virus (HBV). In the context of a clinical trial (NCT02057263) conducted by Massachusetts General Hospital, this standard vaccine was evaluated in healthy adults aged 40-70 to determine if the bisphosphonate medication alendronate could serve as an adjuvant to enhance the humoral immune response. The vaccine works by stimulating the immune system to produce neutralizing antibodies (anti-HBs) against the viral surface antigen, providing long-term protection against the pathogen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hepatitis B vaccine (Massachusetts General Hospital).